Issues related to the Patient Protection and Affordable Care Act, P.L. 111-148: Medicare funding issues, and the American Taxpayer Relief Act of 2012, P.L. 112-240. Issues related to Protecting Seniors' Access to Medicare Act of 2013, S.351. Issues related to Medicare Part D and deficit reduction.
Issues related to patent reform. Patent Transparency and Improvements Act of 2013, S. 1720.
Issues related to the implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, P.L. 112-144.
Issues related to pharmaceutical importation.
Issues related to generic drugs.
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act, P.L. 113-54.
The Continuing Appropriations Resolution, 2014, H.R.3547/P.L. 113-76; issues related to the Budget Act and user fees.
Duration: February 22, 2011
to
April 1, 2014
General Issues: Medicare/Medicaid , Copyright/Patent/Trademark , Health Issues , Pharmacy , Budget/Appropriations
Spending: about $750,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2011: House of Representatives, U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2014
The Ingram Group LLC DBA The FIRST Group terminated an engagement in which they represented Pharmaceutical Research and Manufacturers of America (PhRMA) on July 17, 2014.
Original Filing: 300659792.xml
1st Quarter, 2014
In Q1, The Ingram Group LLC DBA The FIRST Group lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $60,000. The report was filed on April 16, 2014.
Original Filing: 300637009.xml
Lobbying Issues
Issues related to the Patient Protection and Affordable Care Act, P.L. 111-148: Medicare funding issues, and the American Taxpayer Relief Act of 2012, P.L. 112-240. Issues related to Protecting Seniors' Access to Medicare Act of 2013, S.351. Issues related to Medicare Part D and deficit reduction.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to patent reform. Patent Transparency and Improvements Act of 2013, S. 1720.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, P.L. 112-144.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical importation.
Issues related to generic drugs.
Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act, P.L. 113-54.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
The Continuing Appropriations Resolution, 2014, H.R.3547/P.L. 113-76; issues related to the Budget Act and user fees.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, The Ingram Group LLC DBA The FIRST Group lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $60,000. The report was filed on Jan. 17, 2014.
Original Filing: 300618925.xml
Lobbying Issues
Issues related to the Patient Protection and Affordable Care Act, P.L. 111-148: Medicare funding issues, and the American Taxpayer Relief Act of 2012, Public Law No: 112-240. Issues related to Protecting Seniors' Access to Medicare Act of 2013, S.351.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to patent reform. Patent Transparency and Improvements Act of 2013, S. 1720.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, Public Law No: 112-144.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical importation, issues related to generic drugs, issues related to the Budget Act and user fees and S.CON.RES.8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023. Issues related to the Drug Supply Chain Security Act of 2013, S.957.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the Bipartisan Budget Act of 2013, H.J.Res.59.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, The Ingram Group LLC DBA The FIRST Group lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $60,000. The report was filed on Oct. 17, 2013.
Original Filing: 300597503.xml
Lobbying Issues
Issues related to the Patient Protection and Affordable Care Act, P.L. 111-148: Medicare funding issues, and the American Taxpayer Relief Act of 2012, Public Law No: 112-240. Issues related to Protecting Seniors' Access to Medicare Act of 2013, S.351.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to patent reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, Public Law No: 112-144.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical importation, issues related to generic drugs, and S.CON.RES.8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023. Issues related to the Drug Supply Chain Security Act of 2013 S.957.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, The Ingram Group LLC DBA The FIRST Group lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $60,000. The report was filed on July 18, 2013.
Original Filing: 300577021.xml
Lobbying Issues
Issues related to the Patient Protection and Affordable Care Act, P.L. 111-148: Medicare funding issues, and the American Taxpayer Relief Act of 2012, Public Law No: 112-240. Issues related to Protecting Seniors' Access to Medicare Act of 2013, S.351.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to patent reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, Public Law No: 112-144.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical importation, issues related to generic drugs, and S.CON.RES.8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023. Issues related to the Drug Supply Chain Security Act of 2013 S.957.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, The Ingram Group LLC DBA The FIRST Group lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $60,000. The report was filed on April 16, 2013.
Original Filing: 300551230.xml
Lobbying Issues
Issues related to the Patient Protection and Affordable Care Act, P.L. 111-148: Medicare issues related to the Independent Payment Advisory Board (IPAB), Medicare funding issues, and the American Taxpayer Relief Act of 2012, Public Law No: 112-240.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to patent reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, Public Law No: 112-144.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical importation, issues related to generic drugs, and S.CON.RES.8, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, The Ingram Group LLC DBA The FIRST Group lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $60,000. The report was filed on Jan. 19, 2013.
Original Filing: 300536155.xml
Lobbying Issues
Issues related to the Patient Protection and Affordable Care Act, P.L. 111-148: Medicare issues related to the Independent Payment Advisory Board (IPAB), Medicare funding issues, P.L. 112-25, the Budget Control Act of 2011 and the American Taxpayer Relief Act of 2012, H.R. 8.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the Patent Reform Act of 2011, S.23.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, Public Law No: 112-144.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical importation, generic drug pricing and the FAIR Generics Act, S.1882.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, The Ingram Group LLC DBA The FIRST Group lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $60,000. The report was filed on Oct. 18, 2012.
Original Filing: 300510726.xml
Lobbying Issues
Issues related to the Patient Protection and Affordable Care Act, P.L. 111-148: Medicare issues related to the Independent Payment Advisory Board (IPAB), Medicare funding issues, P.L. 112-25, and the Budget Control Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the Patent Reform Act of 2011, S.23.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Prescription Drug User Fee Act (PDUFA) reauthorization, S.3187.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical importation and generic drug pricing, S.3187, and the FAIR Generics Act, S.1882.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, The Ingram Group LLC DBA The FIRST Group lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $60,000. The report was filed on July 19, 2012.
Original Filing: 300493334.xml
Lobbying Issues
Issues related to the Patient Protection and Affordable Care Act, P.L. 111-148: Medicare issues related to the Independent Payment Advisory Board (IPAB), Medicare funding issues, P.L. 112-25, and the Budget Control Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the Patent Reform Act of 2011, S.23.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Prescription Drug User Fee Act (PDUFA) reauthorization, S.3187.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical importation and generic drug pricing, S.3187.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, The Ingram Group LLC DBA The FIRST Group lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $60,000. The report was filed on April 17, 2012.
Original Filing: 300462128.xml
Lobbying Issues
Issues related to the Patient Protection and Affordable Care Act, P.L. 111-148: Medicare issues related to the Independent Payment Advisory Board (IPAB), and Medicare funding issues, P.L. 112-25, the Budget Control Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to S.23, Patent Reform Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to Prescription Drug User Fee Act (PDUFA) reauthorization.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical importation.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, The Ingram Group LLC DBA The FIRST Group lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $60,000. The report was filed on Jan. 18, 2012.
Original Filing: 300440276.xml
Lobbying Issues
Issues related to the Patient Protection and Affordable Care Act, P.L. 111-148: Medicare payment issues including the Independent Payment Advisory Board (IPAB) and Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to S.23, Patent Reform Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S.1323, A bill to express the sense of the Senate on shared sacrifice in resolving the budget deficit; issues related to the debt ceiling.
Deficit issues related to Medicare and Medicaid and S. 365, The Budget Control Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical importation, H.R. 2112, The Consolidated and Further Continuing Appropriations Act of 2012.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, The Ingram Group LLC DBA The FIRST Group lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $60,000. The report was filed on Oct. 18, 2011.
Original Filing: 300418073.xml
Lobbying Issues
Issues related to the Patient Protection and Affordable Care Act: Medicare payment issues including the Independent Payment Advisory Board (IPAB) and Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to S.23, Patent Reform Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S.1323, A bill to express the sense of the Senate on shared sacrifice in resolving the budget deficit; issues related to the debt ceiling.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, The Ingram Group LLC DBA The FIRST Group lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $60,000. The report was filed on July 19, 2011.
Original Filing: 300398866.xml
Lobbying Issues
Issues related to the Patient Protection and Affordable Care Act: Medicare payment issues including the Independent Payment Advisory Board (IPAB) and Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to S.23, Patent Reform Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to the debt ceiling.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, The Ingram Group LLC DBA The FIRST Group lobbied for Pharmaceutical Research and Manufacturers of America (PhRMA) , earning $30,000. The report was filed on April 19, 2011.
Original Filing: 300372976.xml
Lobbying Issues
Issues related to the Patient Protection and Affordable Care Act: Medicare payment issues including the Independent Payment Advisory Board (IPAB) and S.23, Patent Reform Act of 2011.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
The Ingram Group LLC DBA The FIRST Group filed a lobbying registration on April 5, 2011 to represent Pharmaceutical Research and Manufacturers of America (PhRMA), effective Feb. 22, 2011.
Original Filing: 300360705.xml
Issue(s) they said they’d lobby about: Issues related to the Patient Protection and Affordable Care Act: Medicare payment issues including the Independent Payment Advisory Board (IPAB) and S.23, Patent Reform Act of 2011. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...